Biocartis Announces Nine Idylla™ Studies Published at AMP 2022 Annual Meeting
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracy, ease-of-use and rapid time-to-results.
Biocartis Idylla™ GeneFusion Panel
Products are for professional/laboratory use only Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1 and RET fusions & MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections from patients with NSCLC.
New Study Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions
Products are for professional/laboratory use only. New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) This study shows that Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods:
New Study Shows Rapid EGFR testing with Idylla!
Products are for professional/laboratory use only. Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
Biocartis Launches Liquid Biopsy Idylla™ ctEGFR Mutation Assay (RUO)
Products are for professional/laboratory use only. Biocartis is pleased to announce the launch of the Idylla™ ctEGFR Mutation Assay (RUO1). This assay is the liquid biopsy version of the solid biopsy Idylla™ EGFR Mutation Test (CE-IVD).
Biocartis announces CE-IVD marking of its Idylla™ MSI Test
Products are for professional/laboratory use only. Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE[1] colorectal cancer tumor tissue. This CE-IVD […]